Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Express News | CEL-SCI Shares Resume Trade
Express News | CEL-SCI Shares Halted On Circuit Breaker To The Downside, Stock Now Up 21.9%
Express News | CEL-SCI Corporation Prices Best-Efforts Offering Of 10.845M Shares And Pre-Funded Warrants At $1.00 Each, Expected To Raise $10.845M; Closing On July 29, 2024
Express News | CEL-SCI Corp - Offering Price Set at $1.00 per Share
Express News | CEL-SCI Announces Pricing of $10.8 Million Offering
Express News | Amex Halt News Pending Lst 1.475000
Express News | CEL-SCI Shares Are Trading Higher After the Company Announced Results From a Bias Analysis Conducted for Its Concluded Phase 3 Study of Multikine. Multikine Cut the 5-year Risk of Death by Half Compared to Control in Its Target Population
Express News | CEL-SCI - Data Supports Clinical Effect of Neoadjuvant (Pre-Surgery) Multikine Immunotherapy in Extending Life of Patients in Phase 3 Study
Express News | CEL-SCI Corp - Study Data Are Reliably Interpretable, Statistically Significant
Express News | Cel-Sci’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
Express News | CEL-SCI Appoints Robert Watson as Chairperson of the Board
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
Express News | CEL-SCI Q2 2024 GAAP EPS $(0.28) Misses $(0.14) Estimate
Express News | CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI 2Q Loss/Shr 14c >CVM
CEL-SCI | 10-Q: Quarterly report
CEL-SCI(CVM.US) Director Buys US$27,800 in Common Stock
CEL-SCI(CVM.US) Officer Buys US$11,120 in Common Stock